ЭФФЕКТИВНАЯ ИНАКТИВАЦИЯРЕНИН-АНГИОТЕНЗИН-АЛЬДОСТЕРОНОВОЙ СИСТЕМЫ: ВЫБОР В ПОЛЬЗУ ИНГИБИТОРОВ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА
Аннотация
В обзорной статье проведена сравнительная оценка эффективности двух классов лекарственных препаратов — ингибиторов ангиотензинпревращающего фермента и блокаторов рецепторов ангиотензина II в профилактике сердечно-сосудистых заболеваний по данным ряда метаанализов. Показано, что блокаторы рецепторов ангиотензина II не обеспечивают эффективной защиты от основных сердечно-сосудистых рисков у больных ишемической болезнью сердца и цереброваскулярными болезнями.
Об авторе
С. В. Столов
Северо-Западный государственный медицинский университет имени И.И. Мечникова, Санкт-Петербург
Россия
Россия
Доктор медицинских наук, заместитель главного терапевта Санкт-Петербурга, профессор кафедры терапии и ревматологии имени Э.Э. Эйхвальда ГБОУ ВПО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава России.
Контактная информация: ГБОУ ВПО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Минздрава России, ул. Кирочная, д. 41, Санкт-Петербург, Россия, 191015. E-mail: sergey.stolov@spbmapo.ru (Столов Сергей Валентинович).
Список литературы
1. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. — 2001. — Vol. 345, № 12. — P. 851–860.
2. Papademetriou V., Farsang C., Elmfeldt D. et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension:the Study on Cognition and Prognosis in the Elderly (SCOPE) // J. Am. Coll. Cardiol. — 2004. — Vol. 44, № 6. — P. 1175–1180.
3. Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction // Br. Med. J. — 2004. — Vol. 329, № 7477. — P. 1248–1249.
4. Strauss M.H., Hall A.S. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin receptor blockers may increase risk of myocardial infarction. Unraveling the ARB-MI paradox // Circulation. — 2006. — Vol. 114, № 8. — P. 838–854.
5. Turnbull F., Neal B., Algert C. et al. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. — 2005. — Vol. 165, № 12. — P. 1410–1419.
6. Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359, № 9311. — P. 995–1003.
7. McDonald M.A., Simpson S.H., Ezekowitz J.A. et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review // Br. Med. J. — 2005. — Vol. 331, № 7521. — P. 873–879.
8. Tsuyuki R.T., McDonald M.A. Angiotensin receptor blockers do not increase risk of myocardial infarction // Circulation. — 2006. — Vol. 114, № 8. — P. 855–860.
9. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies // Br. Med. J. — 2009. — № 338. — b1665. — doi: 10.1136/bmj.b1665.
10. Sawada T., Yamada H., Dahlof B., Matsubara H. KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study // Eur. Heart J. — 2009. — Vol. 30, № 20. — P. 2461–2469.
11. Messerli F.H., Bangalore S., Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? // Eur. Heart J. — 2009. — Vol. 30, № 20. — P. 2427–2430.
12. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fi brillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program // Am. Heart J. — 2006. — Vol. 152, № 1. — P. 86–92.
13. Mochizuki S., Dahlf B., Shimizu M. et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity—mortality study // Lancet. — 2007. — Vol. 369, № 9571. — P. 1431–1439.
14. Strauss M.H., Lonn E.M., Verma S. Is the jury out? Class specifi c differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists Collaboration // Eur. Heart J. — 2005. — Vol. 26, № 22. — P. 2351–2353.
15. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial // Lancet. — 2004. — Vol. 363, № 9426. — P. 2022–2031.
16. Al Khalaf M.M., Thalib L., Doi S.A. Cardiovascular Outcomes in high-risk patients without heart failure treated with ARBs: a Systematic Review and Meta-Analysis // Am. J. Cardiovasc. Drugs. — 2009. — Vol 9, №1. — P. 29–43.
17. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND)Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. — 2008. — Vol. 372, № 9644. — P. 1174–1183.
18. Yusuf S., Diener H.C., Sacco R.L. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. — 2008. — Vol. 359, № 12. — P. 1225–1237.
19. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association / American Stroke Association // Stroke. — 2011. — Vol. 42, № 1. — P. 227–276; originally published online Oct. 21, 2010.
20. 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 10. — P. 1281–1357.
21. Brenner B.M., Cooper M.E., de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy // N. Engl. J. Med. — 2001. — Vol. 345, № 12. — P. 861–869.
22. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. —2001. — Vol. 345, № 12. — P. 851–860.
23. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians / American College of Cardiology Foundation / American Heart Association / American Association for Thoracic Surgery / Preventive Cardiovascular Nurses Association / Society of Thoracic Surgeons // Ann. Intern. Med. — 2012. — Vol. 157, № 10. — P. 735–743.
24. 2013 ESC guidelines on the management of stable coronary artery disease // Eur. Heart J. — 2013. – Vol. 34, № 38. – Р. 2949–3003. doi:10.1093/eurheartj/eht296.
25. Van Vark L.C., Bertrand M., Akkerhuis K.M. et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients // Eur. Heart J. – 2012. – Vol. 33, № 16. — Р. 2088–2097. doi: 10.1093/eurheartj/ehs075. Advance Access published. — April 17, 2012.
26. Savarese G., Costanzo P., Cleland J.G. et al. A meta-analisis reporting effects of angiotensin-converting enzyme ingibitor and angiotensin receptor blockers in patients without heart failure // J. Am. Coll. Cardiol. — 2013. — Vol. 61, № 2. — P. 131–142.
27. Sipahi I., Debanne S.M., Rowland D.Y. et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials // Lancet Oncol. — 2010. — Vol. 11, № 7. — P. 627–636.
28. Nissen S.E. Angiotensin-receptor blockers and cancer: urgent regulatory review needed // Lancet Oncol. — Vol. 11, № 7. — P. 605–606.
29. Ferrari E., Boersma E. The impact of ACE ingibitor on all-cause and cardiovascular mortality in contemporary hypertension trials: a review // Expert Rev. Cardiovasc. Ther. — 2013. — Vol. 11, № 6. — P. 705–717.
Для цитирования:
Столов С.В. ЭФФЕКТИВНАЯ ИНАКТИВАЦИЯРЕНИН-АНГИОТЕНЗИН-АЛЬДОСТЕРОНОВОЙ СИСТЕМЫ: ВЫБОР В ПОЛЬЗУ ИНГИБИТОРОВ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА. Артериальная гипертензия. 2014;20(4):307-319. https://doi.org/10.18705/1607-419X-2014-20-4-307-319
For citation:
Stolov S.V. EFFECTIVE INHIBITION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM: THE ANGIOTENSIN-CONVERTING ENZYME INHIBITORS BENEFITS. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2014;20(4):307-319. (In Russ.) https://doi.org/10.18705/1607-419X-2014-20-4-307-319
Просмотров: 290
Послать статью по эл. почте 